奥马珠单抗成功治疗难治性哮喘持续状态：一例报告
Successful treatment of refractory status asthmaticus with omalizumab: a case report.
作者信息
Benes Jan, Skulec Roman, Jilek Dalibor, Fibigr Ondrej, Cerny Vladimir
机构信息
Faculty of Medicine in Hradec Kralove, Charles University in Prague, University Hospital Hradec Kralove, Hradec Kralove, Czechia.
Dept. of Anesthesiology, Perioperative Medicine and Intensive Care, Masaryk Hospital, J.E. Purkinje University, Usti nad Labem, Czechia.
出版信息
Allergy Asthma Clin Immunol. 2021 Dec 9;17(1):128. doi: 10.1186/s13223-021-00629-z.
Refractory status asthmaticus is the cause of rare cases of in-hospital death due to acute bronchial asthma. The most severe cases unresponsive to first, second and next line treatment may be fatal despite aggressive organ support with invasive ventilation and extracorporeal membrane oxygenation. Omalizumab, a humanized recombinant monoclonal anti-IgE antibody, is an approved add-on biological treatment for severe asthma. However, it is not indicated in an acute setting. Here, we report the case of a young patient with status asthmaticus fully dependent on extracorporeal membrane oxygenation refractory to any therapy for six days, who was successfully treated with omalizumab.
难治性哮喘持续状态是急性支气管哮喘导致院内死亡的罕见原因。尽管采用有创通气和体外膜肺氧合进行积极的器官支持治疗，对一线、二线及后续治疗均无反应的最严重病例仍可能致命。奥马珠单抗是一种人源化重组单克隆抗IgE抗体，是一种已获批准用于重度哮喘的附加生物治疗药物。然而，它不适用于急性发作期。在此，我们报告一例哮喘持续状态的年轻患者，该患者完全依赖体外膜肺氧合，对任何治疗均无反应达6天，最终使用奥马珠单抗成功治愈。
Zotero 插件